Navigation Links
Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
Date:4/24/2009

nce the therapeutic effects of exenatide by ensuring patient compliance and providing more consistent, round-the-clock therapeutic drug levels; and to reduce side effects, including nausea, associated with high peak levels of exenatide exposure observed with injection administration. Unlike other extended delivery technologies such as polymers or albumin fusion, DUROS delivery allows for steady state drug delivery upon insertion and near immediate withdrawal of therapy to manage side effects, if required.

"We are very pleased with the rapid progress the Company has made with ITCA 650," said Alice Leung, President & CEO of Intarcia. "Our team has demonstrated the great potential for DUROS delivered therapies in advancing this important treatment candidate for type 2 diabetes patients from an idea to clinical stage development in 18 months."

ITCA 650 is the second DUROS delivery program Intarcia has moved into clinical development. In December 2008, Intarcia also completed enrollment of a phase 1b study for ITCA 638, which involves DUROS delivery of omega interferon for the treatment of chronic hepatitis C infection. "Many patients with type 2 diabetes are forced to manage dosing schedules and side effects of multiple drug therapies simultaneously to adequately control their disease," commented Ken Luskey, M.D., VP, Clinical Research at Intarcia. "We believe ITCA 650 will deliver improved glycemic control and provide a better tolerated, more convenient treatment option."

About Intarcia

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to ensure enhanced treatment outcome by optimizing patient adherence and improving the convenience and tolerability of drug therapies. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above body temperature and to deliver them in a constant and consistent manner via
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014 BRIC Biopsy Devices Market ... GlobalData,s new report, "BRIC Biopsy Devices Market Outlook to ... Devices market. The report provides value, in millions of ... US dollars) within market segments - Biopsy Guns (Disposable ... Aspiration Needles (Disposable and Reusable Fine Aspiration Needles) and ...
(Date:9/17/2014)... YORK , Sept. 17, 2014 ... 2020 Summary GlobalData,s ... 2020", provides key market data on the Brazil ... millions of US dollars, volume (in units) and ... - Female Sterilization Devices (Transcervical Sterilization Devices (Micro-inserts) ...
(Date:9/17/2014)... 2014 The ambulance equipment industry ... due to the recession, an unstable health ... This BCC Research report analyzes present and ... ambulance and emergency medical services equipment market ... control devices, equipment used for burn care, ...
Breaking Medicine Technology:BRIC Biopsy Devices Market Outlook to 2020 2BRIC Biopsy Devices Market Outlook to 2020 3Brazil Gynecological Devices Market Outlook to 2020 2Brazil Gynecological Devices Market Outlook to 2020 3Ambulance and Emergency Equipment: Global Markets 2Ambulance and Emergency Equipment: Global Markets 3Ambulance and Emergency Equipment: Global Markets 4
... SAN DIEGO, Nov. 2, 2011 Amylin Pharmaceuticals, Inc. (Nasdaq: ... Suisse 2011 Healthcare Conference in Phoenix on Wednesday, November 9, ... M. Bradbury, president and chief executive officer, Amylin Pharmaceuticals, will ... webcast live through the "Investors" section of Amylin,s corporate website ...
... Inc. (NASDAQ: IPHS ), the leading North ... beverage, pharmaceutical, oral care and industrial end markets, today ... and completed the acquisition of Kelatron Corporation. ... manufacturer of bioactive mineral nutrients. For over 30 years, ...
Cached Medicine Technology:Innophos Holdings, Inc. Announces Acquisition of Kelatron Corporation 2
(Date:9/17/2014)... TX (PRWEB) September 17, 2014 North ... were recently granted several awards for their top-notch services. ... patient experience, orthopedic care and GYN surgery. , Hospital-wide, ... Safety Excellence Award™. They have received this award for ... among the top 5 percent in the nation for ...
(Date:9/17/2014)... News) -- A blood test that measures DNA from ... better assessment of the state of a man,s disease, ... this blood test could reveal when treatment for ... tumor growth, the researchers suggested. "Our study showed ... prostate cancer and often initially very effective started to ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Wright ... Conserve line of metal-on-metal hip replacements continue to ... U.S. District Court, Northern District of Georgia, Bernstein ... List issued by the U.S. Judicial Panel on ... 397 product liability claims have been filed in ...
(Date:9/17/2014)... are Asian Americans at higher risk of developing type ... the disease at lower body weights? One part of ... high-fiber, low-fat Asian diets to current westernized diets, which ... says George King, M.D., Senior Vice President and Chief ... author of the study. , A Joslin randomized clinical ...
(Date:9/17/2014)... London, UK (PRWEB) September 17, 2014 ... of the total medical technology market, focusing on molecular ... cancer, chronic diseases, and genetic testing. The IVD market ... billion by the end of 2017. The major drivers ... testing; need for speed, which is evidenced by the ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center Receives Several Accolades 2Health News:DNA Blood Test Might Identify Status of Prostate Cancer 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 3Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 3
... method of quickly identifying large numbers of the genetic material ... that turns genes on and off. , The method, ... of 22,000 of these "on-off" switches for roughly 600 human ... ultimate impacts on the study of the genetic basis of ...
... Study reports MS medication possession ratio of 86 percent ... Multiple sclerosis patients managed by a specialty pharmacy ... lower risk of being hospitalized for their disease than ... program, according to a study completed by HealthCore, Inc.HealthCore ...
... sold in two separate transactions-- Industrial staffing business ... to fund DailyMed(TM) growthINDIANAPOLIS, May 19 Arcadia ... a leading provider of home care, medical staffing, ... today announced the sale of two non-strategic businesses. ...
... U.S. health officials say the disease is no more ... News) -- The World Health Organization may declare a ... that the virus has swept through Japan, a former ... transmission is now occurring in a region outside North ...
... Minn., May 19 Activeion ... that it has increased its commitment to ... membership organization for institutions and businesses in ... in reducing their environmental footprints.(Logo: ...
... to offer the online social network the chance to ... weigh in at the site, topics of interest to ... 19 FertilityTies ( www.FertilityTies.com ), the ... trying to conceive/facing infertility that combines expertise of accredited ...
Cached Medicine News:Health News:UCSF creates fast, affordable tool for finding gene 'on-off' switches 2Health News:MS Patients More Compliant with Medications When Managed by Specialty Pharmacy, According to HealthCore Study Presented at ISPOR 2Health News:MS Patients More Compliant with Medications When Managed by Specialty Pharmacy, According to HealthCore Study Presented at ISPOR 3Health News:Arcadia Resources Announces Sale of Non-Strategic Businesses 2Health News:Arcadia Resources Announces Sale of Non-Strategic Businesses 3Health News:Arcadia Resources Announces Sale of Non-Strategic Businesses 4Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 2Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 3Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 4Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 5Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 6Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 7Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 8Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 9Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 10Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 11Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 12Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 13Health News:Activeion Cleaning Solutions, LLC Joins National Health Organization Supporting Environmental Practices 2Health News:Activeion Cleaning Solutions, LLC Joins National Health Organization Supporting Environmental Practices 3Health News:FertilityTies.com Convention Open to the Public, June 6, 1-5 PM at The Hilton New York Hotel, MDs to Lead Discussion on Timely Fertility Topics 2
... 6000 lets you manually ... precise positioning. The superior ... immediate and exact positioning ... making it especially effective ...
The Total Toe System offers a new generation in first metatarsophalangeal joint reconstruction....
The Acumed Great Toe System is a two-piece non-constrained implant for the first MP joint. The system was developed to provide ease of use for the surgeon, combined with precise instrumentation and a...
The design features of the Mini Lag Screw System simplify the screw fixation by reducing possible sources of error, reducing instrumentation, and decreasing the time of fixation....
Medicine Products: